Jolanta Opacka-Juffry

List of Publications by Year
in descending order

52	1,995	236612	243296
papers	citations	25 h-index	44 g-index

53	53	53	2096
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quantitation of Carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse, 1992, 12, 47-54.	0.6	198
2	Distribution and quantification of immunoreactive orexin A in rat tissues. FEBS Letters, 1999, 457, 157-161.	1.3	156
3	Long-term effects of early life deprivation on brain glia in Fischer rats. Brain Research, 2007, 1142, 119-126.	1.1	114
4	Experience of stress in childhood negatively correlates with plasma oxytocin concentration in adult men. Stress, 2012, 15, 1-10.	0.8	101
5	Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. Synapse, 1995, 21, 45-53.	0.6	91
6	Longâ€term protection of the rat nigrostriatal dopaminergic system by glial cell lineâ€derived neurotrophic factor against 6â€hydroxydopamine in vivo. European Journal of Neuroscience, 1998, 10, 57-63.	1.2	85
7	Effect of 5-HT on binding of [11C] WAY 100635 to 5-HT1A receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine. Synapse, 2001, 41, 150-159.	0.6	80
8	Nomifensine-induced increased in extracellular striatal dopamine is enhanced by isoflurane anaesthesia. Synapse, 1991, 7, 169-171.	0.6	70
9	Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain. European Journal of Pharmacology, 1994, 271, 515-523.	1.7	69
10	Early deprivation leads to long-term reductions in motivation for reward and 5-HT1A binding and both effects are reversed by fluoxetine. Neuropharmacology, 2009, 56, 692-701.	2.0	67
11	Coexistence of Gonadotrophin-Releasing Hormone and Galanin: Immunohisto-chemical and Functional Studies. Journal of Neuroendocrinology, 1990, 2, 107-111.	1.2	63
12	GDNF protects against 6-OHDA nigrostriatal lesion. NeuroReport, 1995, 7, 348-352.	0.6	60
13	Chronic social stress induces peripheral and central immune activation, blunted mesolimbic dopamine function, and reduced reward-directed behaviour in mice. Neurobiology of Stress, 2018, 8, 42-56.	1.9	56
14	L-Dihydroxyphenylalanine and its decarboxylase: New ideas on their neuroregulatory roles. Movement Disorders, 1995, 10, 241-249.	2.2	52
15	Regulation of rat pituitary cocaine- and amphetamine-regulated transcript (CART) by CRH and glucocorticoids. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E583-E590.	1.8	52
16	Assessment of striatal graft viability in the rat in vivo using a small diameter PET scanner. NeuroReport, 1995, 6, 2017-2021.	0.6	51
17	Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease. Neuroscience Letters, 1997, 233, 73-76.	1.0	50
18	The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 57-63.	2.5	50

#	Article	IF	Citations
19	Pindolol occupancy of 5-HT1A receptors measured in vivo using small animal positron emission tomography with carbon-11 labeled WAY 100635. , 2000, 36, 330-341.		43
20	Evaluation of [4-O-methyl-11C]KW-6002 as a potential PET ligand for mapping central adenosine A2A receptors in rats. Synapse, 2001, 42, 164-176.	0.6	42
21	Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events. Advances in Pharmacology, 2017, 80, 135-168.	1.2	40
22	Psychometric and neurobiological assessment of resilience in a non-clinical sample of adults. Psychoneuroendocrinology, 2013, 38, 2099-2108.	1.3	37
23	Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration. Brain Research, 1999, 818, 176-179.	1.1	29
24	Evaluation in rat of RS-79948-197 as a potential PET ligand for central Î±2-adrenoceptors. European Journal of Pharmacology, 1996, 317, 67-73.	1.7	28
25	Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Research, 1998, 810, 27-33.	1.1	27
26	Modulatory effects of L-DOPA on D2 dopamine receptors in rat striatum, measured using in vivo microdialysis and PET. Journal of Neural Transmission, 1998, 105, 349.	1.4	26
27	Behavioural and biochemical responses to morphine associated with its motivational properties are altered in adenosine A_{2A} receptor knockout mice. British Journal of Pharmacology, 2008, 155, 757-766.	2.7	22
28	Emotional suppression explains the link between early life stress and plasma oxytocin. Anxiety, Stress and Coping, 2014, 27, 466-475.	1.7	21
29	Evaluation of [O-methyl - 11 C]RS-15385-197 as a positron emission tomography radioligand for central Î± 2 -adrenoceptors. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 475-484.	3.3	20
30	Stimulant mechanisms of cathinones â€" Effects of mephedrone and other cathinones on basal and electrically evoked dopamine efflux in rat accumbens brain slices. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 122-130.	2.5	19
31	Electroencephalography (EEG) Measures of Neural Connectivity in the Assessment of Brain Responses to Salient Auditory Stimuli in Patients with Disorders of Consciousness. Frontiers in Psychology, 2016, 7, 397.	1.1	19
32	Chronic social stress in mice alters energy status including higher glucose need but lower brain utilization. Psychoneuroendocrinology, 2020, 119, 104747.	1.3	19
33	Sensitive method for determination of picogram amounts of epinephrine and other catecholamines in microdissected samples of rat brain using liquid chromatography with electrochemical detection. Biomedical Applications, 1988, 433, 41-51.	1.7	18
34	Evaluation of [11C]RTI-121 as a selective radioligand for PET studies of the dopamine transporter. Nuclear Medicine and Biology, 1996, 23, 377-384.	0.3	17
35	Combined in vitro and in silico approaches to the assessment of stimulant properties of novel psychoactive substances â€“ The case of the benzofuran 5-MAPB. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 1-9.	2.5	17
36	Mechanistic Insights into the Stimulant Properties of Novel Psychoactive Substances (NPS) and Their Discrimination by the Dopamine Transporterâ€"In Silico and In Vitro Exploration of Dissociative Diarylethylamines. Brain Sciences, 2018, 8, 63.	1.1	15

#	Article	IF	Citations
37	Development of central 5-HT2A receptor radioligands for PET: Comparison of [3H]RP 62203 and [3H]SR 46349B kinetics in rat brain. Nuclear Medicine and Biology, 1996, 23, 245-250.	0.3	12
38	In vivo dopaminergic and behavioral responses to acute cocaine are altered in adenosine A_{2A} receptor knockout mice. Synapse, 2012, 66, 383-390.	0.6	12
39	Lack of permanent nigrostriatal dopamine deficit following 6-hydroxydopamine injection into the rat striatum. Journal of Neural Transmission, 1996, 103, 1429-1434.	1.4	10
40	Region- and receptor-specific effects of chronic social stress on the central serotonergic system in mice. IBRO Neuroscience Reports, 2021, 10, 8-16.	0.7	8
41	Astroglial Plasticity Is Implicated in Hippocampal Remodelling in Adult Rats Exposed to Antenatal Dexamethasone. Neural Plasticity, 2015, 2015, 1-8.	1.0	7
42	The Role of Dopamine in the Stimulant Characteristics of Novel Psychoactive Substances (NPS)â€"Neurobiological and Computational Assessment Using the Case of Desoxypipradrol (2-DPMP). Frontiers in Pharmacology, 2020, 11, 806.	1.6	6
43	Catecholamine synthesis inhibitors increase pineal adrenaline content by stimulating adrenal medullary activity. Neuroscience, 1991, 42, 291-297.	1.1	5
44	Disentangling the link between depressive symptoms and plasma oxytocin in men: The role of brooding rumination. Hormones and Behavior, 2015, 75, 142-149.	1.0	4
45	Molecular Mechanisms of Action of Stimulant Novel Psychoactive Substances (NPS) that target the High-affinity Transporter for Dopamine. Neuronal Signaling, 2021, 5, NS20210006.	1.7	3
46	Small Animal PET Enables Parametric Mapping of Saturation Kinetics at the 5-HT1A Receptor. , 2001, , 171-176.		2
47	The role of serotonin as a neurotransmitter in health and illness: A review. British Journal of Neuroscience Nursing, 2008, 4, 272-277.	0.1	1
48	Preclinical Development of a Radioligand for the Study of Central 5-HT1A Receptors with PET â€" [11C]Way-100635. , 1995, , 93-108.		1
49	Combined in Vitro and in Silico Approaches to the Assessment of Stimulant Properties of Novel Psychoactive Substances. Biophysical Journal, 2017, 112, 338a-339a.	0.2	0
50	Using Computational and Neurobiological Methods to Characterise the Stimulant Properties of Novel Psychoactive Substances (NPS) at the Dopamine Transporter. Biophysical Journal, 2021, 120, 123a.	0.2	0
51	Modulatory Effects of Levodopa on D2 Dopamine Receptors in Striatum Assessed Using In Vivo Microdialysis and PET. , 2005, , 261-275.		0
52	Behind a Great Drug There Is a Great Scientist: The Discovery of a Treatment for Parkinsonâ€™s Disease. Frontiers for Young Minds, 0, 8, .	0.8	0